Harada H - Search Results

1

Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.

Omori S, Harada H, Mori K, Hisamatsu Y, Tsuboguchi Y, Yoshioka H, Morinaga R, Daga H, Kurata T, Takahashi T. Omori S, et al. Among authors: harada h. Invest New Drugs. 2022 Feb;40(1):106-114. doi: 10.1007/s10637-021-01155-w. Epub 2021 Sep 8. Invest New Drugs. 2022. PMID: 34495421 Clinical Trial.

2

Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer.

Harada H, Yamamoto N, Takahashi T, Endo M, Murakami H, Tsuya A, Nakamura Y, Ono A, Igawa S, Shukuya T, Tamiya A, Nishimura T. Harada H, et al. Int J Clin Oncol. 2009 Dec;14(6):507-12. doi: 10.1007/s10147-009-0907-2. Epub 2009 Dec 5. Int J Clin Oncol. 2009. PMID: 19967486

3

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.

Shukuya T, Takahashi T, Naito T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Murakami H, Harada H, Mitsuya K, Endo M, Nakasu Y, Takahashi K, Yamamoto N. Shukuya T, et al. Among authors: harada h. Lung Cancer. 2011 Dec;74(3):457-61. doi: 10.1016/j.lungcan.2011.04.007. Epub 2011 May 14. Lung Cancer. 2011. PMID: 21571388

4

Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).

Harada H, Seto T, Igawa S, Tsuya A, Wada M, Kaira K, Naito T, Hayakawa K, Nishimura T, Masuda N, Yamamoto N. Harada H, et al. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1777-82. doi: 10.1016/j.ijrobp.2011.03.037. Epub 2011 May 27. Int J Radiat Oncol Biol Phys. 2012. PMID: 21621337 Clinical Trial.

5

Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.

Inomata M, Shukuya T, Takahashi T, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Yamamoto N. Inomata M, et al. Among authors: harada h. Anticancer Res. 2011 Dec;31(12):4519-23. Anticancer Res. 2011. PMID: 22199325

6

Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.

Shukuya T, Takahashi T, Harada H, Akamatsu H, Sakaguchi C, Imai H, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N. Shukuya T, et al. Among authors: harada h. Anticancer Res. 2012 Feb;32(2):675-80. Anticancer Res. 2012. PMID: 22287762

7

[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].

Mitsuya K, Nakasu Y, Mizokami Y, Takahashi T, Nakamura Y, Ono A, Toda Y, Yamamoto N, Harada H, Nishimura T. Mitsuya K, et al. Among authors: harada h. No Shinkei Geka. 2012 Jun;40(6):503-9. No Shinkei Geka. 2012. PMID: 22647509 Japanese.

8

The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.

Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N. Akamatsu H, et al. Among authors: harada h. Am J Clin Oncol. 2014 Apr;37(2):144-7. doi: 10.1097/COC.0b013e31826e04f9. Am J Clin Oncol. 2014. PMID: 23211219

9

Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older.

Shukuya T, Takahashi T, Harada H, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N. Shukuya T, et al. Among authors: harada h. Jpn J Clin Oncol. 2013 Feb;43(2):176-83. doi: 10.1093/jjco/hys197. Epub 2012 Dec 5. Jpn J Clin Oncol. 2013. PMID: 23225910

10

Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.

Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N. Harada H, et al. Clin Lung Cancer. 2013 Jul;14(4):440-5. doi: 10.1016/j.cllc.2013.01.003. Epub 2013 Mar 27. Clin Lung Cancer. 2013. PMID: 23540866 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,621 results

Search Page